EFFECTS OF PROSTACYCLIN (PGI₂) AND ADENOSINE (ASN) ON TOTAL AND REGIONAL BLOOD FLOW OF ISOLATED, COLLATERALIZED DOG HEARTSSCHOLTHOLT J; BIRRINGER H; FIEDLER VB et al.1981; BASIC RES. CARDIOL.; ISSN 0300-8428; DEU; DA. 1981; VOL. 76; NO 3; PP. 313-327; BIBL. 49 REF.Article

A specific B₂-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramiprilLINZ, W; SCHÖLKENS, B. A.British journal of pharmacology. 1992, Vol 105, Num 4, pp 771-772, issn 0007-1188Article

Cardioprotective effects of ACE inhibitors : experimental proof and clinical perspectivesSCHÖLKENS, B. A; LINZ, W.Clinical physiology and biochemistry. 1990, Vol 8, pp 33-43, issn 0252-1164, 11 p., Suppl. 1Conference Paper

Does bradykinin play a role in the cardiac antiischemic effect of the ACE-inhibitors ?MARTORANA, P. A; LINZ, W; SCHOLKENS, B. A et al.Basic research in cardiology. 1991, Vol 86, Num 4, pp 293-296, issn 0300-8428Article

Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in ratsLINZ, W; SCHÖLKENS, B. A; GANTEN, D et al.Clinical and experimental hypertension. Part A, Theory and practice. 1989, Vol 11, Num 7, pp 1325-1350, issn 0730-0077Article

Kinin receptor antagonists : unique probes in basic and clinical researchWIRTH, K. J; HEITSCH, H; SCHÖLKENS, B. A et al.Canadian journal of physiology and pharmacology. 1995, Vol 73, Num 7, pp 797-804, issn 0008-4212Conference Paper

Biological activities of 6-keto-prostaglandin E₁LEWIS, R; SCHÖLKENS, B. A; BECK, G et al.Prostaglandins leukotrienes and medicine. 1984, Vol 16, Num 3, pp 303-324, issn 0262-1746Article

The bradykinin B₂ receptor antagonist WIN 64338 inhibits the effect of des-Arg⁹-bradykinin in endothelial cellsWIRTH, K. J; SCHÖLKENS, B. A; WIEMER, G et al.European journal of pharmacology. Molecular pharmacology section. 1994, Vol 288, Num 1, pp R1-R2, issn 0922-4106Article

Role of angiotensin II receptor antagonism and converting enzyme inhibition in the progression and regression of cardiac hypertrophy in ratsLINZ, W; HENNING, R; SCHÖLKENS, B. A et al.Journal of hypertension. 1991, Vol 9, pp S400-S401, issn 0263-6352, SUP6Conference Paper

Effects of colforsin, trequinsin and isoprenaline on norepinephrine-induced contractions and cyclic nucleotide levels of isolated vascular tissueLINZ, W; WIEMER, G; SCHÖLKENS, B. A et al.Arzneimittel-Forschung. 1988, Vol 38, Num 2, pp 240-243, issn 0004-4172Article

Cardiovascular effects of the converting enzyme inhibitor ramipril (HOE 498) in anesthetized dogs with acute ischemic left ventricular failureSCHOLKENS, B. A; MARTORANA, P. A; GOBEL, H et al.Clinical and experimental hypertension. Part A, Theory and practice. 1986, Vol 8, Num i6, pp 1033-1048, issn 0730-0077Article

Regulation of aortic atrial natriuretic factor and angiotensinogen in experimental hypertensionOGAWA, T; LINZ, W; SCHÖLKENS, B. A et al.Journal of cardiovascular pharmacology. 1998, Vol 32, Num 6, pp 1001-1008, issn 0160-2446Article

Enhancement of cytosolic calcium, prostacyclin and nitric oxide by bradykinin and the ACE inhibitor ramiprilat in porcine brain capillary endothelial cellsWIEMER, G; POPP, R; SCHÖLKENS, B. A et al.Brain research. 1994, Vol 638, Num 1-2, pp 261-266, issn 0006-8993Article

Persistent tissue converting enzyme inhibition following chronic treatment with Hoe498 and MK421 in spontaneously hypertensive ratsUNGER, T; GANTEN, D; LANG, R. E et al.Journal of cardiovascular pharmacology. 1985, Vol 7, Num 1, pp 36-41, issn 0160-2446Article

Novel series of o-substituted 8-quinolines and 4-benzothiazoles as potent antagonists of the bradykinin B₂ receptorsHEITSCH, H; WAGNER, A; SCHÖLKENS, B. A et al.Bioorganic & medicinal chemistry letters (Print). 1999, Vol 9, Num 3, pp 327-332, issn 0960-894XArticle

Experimental evidence for effects of ramipril on cardiac and vascular hypertrophy beyond blood pressure reduction = Clinical interest of low dose of converting enzyme inhibitor : the HYCAR studyLINZ, W; GOHLKE, P; UNGER, T et al.Archives des maladies du coeur et des vaisseaux. 1995, Vol 88, pp 31-34, issn 0003-9683, NS2Conference Paper

Attenuation of atherosclerosis in apolipoprotein E-deficient mice by ramipril is dissociated from its antihypertensive effect and from potentiation of bradykininKEIDAR, S; ATTIAS, J; COLEMAN, R et al.Journal of cardiovascular pharmacology. 2000, Vol 35, Num 1, pp 64-72, issn 0160-2446Article

Bradykinin prevents left ventricular hypertrophy in ratsLINZ, W; WIEMER, G; SCHÖLKENS, B. A et al.Journal of hypertension. Supplement. 1993, Vol 11, Num 5, pp S96-S97, issn 0952-1178Conference Paper

Cardiac and vascular effects of long-term losartan treatment in stroke-prone spontanously hypertensive ratsGOHLKE, P; LINZ, W; SCHÖLKENS, B. A et al.Hypertension (Dallas, Tex. 1979). 1996, Vol 28, Num 3, pp 397-402, issn 0194-911XConference Paper

Technetium-99m-labeled HOE 140 : a potential bradykinin B₂ receptor imaging agentSTAHL, W; BREIPOHL, G; KUHLMANN, L et al.Journal of medicinal chemistry (Print). 1995, Vol 38, Num 15, pp 2799-2801, issn 0022-2623Article

DesArg⁹-D-Arg[Hyp³,Thi⁵,D-Tic⁷,Oic⁸]bradykinin (desArg¹⁰-[Hoe140]) is a potent bradykinin B₁ receptor antagonistWIRTH, K; BREIPOHL, G; STECHL, J et al.European journal of pharmacology. 1991, Vol 205, Num 2, pp 217-218, issn 0014-2999Article

Vascular effects of piretanide. Studies on extrarenal action in several animal modelsKLAUS, E; ALPERMANN, H. G; CASPRITZ, G et al.Arzneimittel-Forschung. 1983, Vol 33, Num 9, pp 1273-1276, issn 0004-4172Article

Ramiprilat increases bradykinin outflow from isolated hearts of ratBAUMGARTEN, C. R; LINZ, W; KUNKEL, G et al.British journal of pharmacology. 1993, Vol 108, Num 2, pp 293-295, issn 0007-1188Article

Ramipril prevents left ventricular hypertrohy with myocardial fibrosis without blood pressure reduction : a one year study in ratsLINZ, W; SCHAPER, J; WIEMER, G et al.British journal of pharmacology. 1992, Vol 107, Num 4, pp 970-975, issn 0007-1188Article

Role of bradykinin in the cardiac effects of angiotensin-converting enzyme inhibitorsLINZ, W; SCHÖLKENS, B. A.Journal of cardiovascular pharmacology. 1992, Vol 20, pp S83-S90, issn 0160-2446, SUP9Conference Paper